Carmignac Gestion Has $7.45 Million Stake in BioNTech SE Sponsored ADR $BNTX

Carmignac Gestion reduced its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 29.1% during the 2nd quarter, HoldingsChannel reports. The firm owned 79,875 shares of the company’s stock after selling 32,836 shares during the quarter. Carmignac Gestion’s holdings in BioNTech were worth $7,448,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in BNTX. Larson Financial Group LLC lifted its position in shares of BioNTech by 86.4% during the 4th quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. EFG International AG bought a new stake in BioNTech during the 4th quarter valued at approximately $29,000. Caitong International Asset Management Co. Ltd grew its holdings in BioNTech by 520.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after buying an additional 260 shares during the last quarter. Tower Research Capital LLC TRC increased its position in BioNTech by 118.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after buying an additional 305 shares during the period. Finally, Vestcor Inc bought a new position in BioNTech in the 4th quarter worth approximately $153,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Stock Performance

BNTX traded down $5.10 during trading on Tuesday, reaching $98.66. 1,127,241 shares of the company’s stock were exchanged, compared to its average volume of 1,114,558. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $96.82 and a 200 day moving average price of $95.61. The company has a market capitalization of $24.95 billion, a P/E ratio of -12.60 and a beta of 1.29.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). The business had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company’s quarterly revenue was down 59.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.60) EPS. As a group, analysts predict that BioNTech SE Sponsored ADR will post -6.33 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. BMO Capital Markets cut BioNTech from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $128.00 to $105.00 in a research report on Tuesday. Citigroup dropped their target price on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Morgan Stanley cut their target price on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating for the company in a research note on Wednesday, July 8th. UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and increased their price target for the company from $117.00 to $135.00 in a report on Wednesday, May 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $126.00.

Insiders Place Their Bets

In related news, CEO Ugur Sahin sold 31,500 shares of the company’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00. Following the sale, the chief executive officer owned 781,709 shares of the company’s stock, valued at $80,922,515.68. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by insiders.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.